Compare ProShares Ultra QQQ ETF (QLD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Twist Bioscience Corp — how do they compare? ProShares Ultra QQQ ETF trades at $90.03, while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). Which is the better fit depends on your goals.
| QLD | TWST | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $153.10 |
52-Week Low | $57.16 | $24.16 |
Market Cap | — | $8.42B |
Enterprise Value | — | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $90.53, down 0.17% with a bullish technical signal from moving averages. The ETF has delivered over 10,000% total return since inception, demonstrating powerful compounding. Recent institutional buying includes 180 Wealth Advisors increasing their position by 29.4% in Q2 2026. Technical indicators show strong moving average support but neutral oscillators, with key support at $88-90 and resistance at $91-93 levels.
As a daily leveraged ETF tracking the Nasdaq-100, QLD offers amplified exposure to large-cap tech but carries inherent volatility risks. The current neutral RSI and ADX suggest consolidation near support levels. Institutional accumulation and strong historical performance support long-term growth potential, though leveraged structure requires careful risk management during market turbulence.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
